ArticleUnited European gastroenterology journal2020
Patterns of liver injury in COVID-19 - a German case series.
Article in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- COVID-19 associated liver injury: An updated review on the mechanisms and management of risk groups.Liver research (Beijing, China) · 2023Review
- Unraveling the Molecular and Cellular Pathogenesis of COVID-19-Associated Liver Injury.Viruses · 2023Review
- Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19.BMC anesthesiology · 2023Article
- Liver injury in hospitalized patients with COVID-19: An International observational cohort study.PloS one · 2023Observational
- COVID-19-Associated Liver Injury.Hepatic medicine : evidence and research · 2023Review
- Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges.Journal of family medicine and primary care · 2022Review
- Liver-spleen axis dysfunction in COVID-19.World journal of gastroenterology · 2021Review
- An overview of SARS-COV-2-related hepatic injury.Hepatology forum · 2021Review
- COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology.United European gastroenterology journal · 2021Review
- Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis.Diseases (Basel, Switzerland) · 2021Review
- Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019.Journal of clinical and translational hepatology · 2021Review
- COVID-19 and comorbidities of hepatic diseases in a global perspective.World journal of gastroenterology · 2021Review
- Implications of SARS-CoV-2 infection for neurogastroenterology.Neurogastroenterology and motility · 2021Review
- The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19.Therapeutic advances in gastroenterology · 2021Article
- Successful liver transplant in a patient with acute cholestatic liver failure due to COVID-19 infection: A case report.Journal of liver transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReports of liver injury in patients with novel coronavirus disease 2019 (COVID-19) are emerging from China and the USA. A wide variety of liver function test abnormalities and few cases of severe liver failure have been reported. No data on the hepatic phenotype from Europe are available at current.
methodsWe report a case series of 44 consecutive patients hospitalized for COVID-19 in Germany.
resultsAt the time of admission, aspartate aminotransferase greater than the upper limit of normal was present in 70%, while alanine aminotransferase was elevated in 15.8%. Markers of cholestatic liver injury were altered only in a minority of patients. During hospitalization, 31% and 22% experienced increasing aspartate aminotransferase and alanine aminotransferase, respectively, when transaminases were normal at admission. Severe liver injury defined by 3×> upper limit of normal was observed in 9.1% over a mean time of 10.5 days. Importantly, patients exhibited cytotoxicity including lactate dehydrogenase and creatinine kinase elevations, but no signs of relevant liver function impairment.
conclusionIn summary, in a case series of hospitalized patients in Germany, cytotoxicity in the absence of severe liver dysfunction at admission and only few cases suggestive of severe liver injury during hospital were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.